Core Insights - SS Innovations has successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), marking a historic milestone in robotic telesurgery [1][4][5] Group 1: Product Overview - The SSi Mantra Tele Surgeon Console is a compact, self-contained, chair-based system designed for telesurgery, allowing operations from various locations, including physician offices [2][4] - The TSC features 3D visualization, magnetic sensor controls, and a smaller footprint compared to traditional operating room setups, enhancing flexibility for surgical experts [7][9] Group 2: Surgical Achievement - Dr. Sudhir Srivastava performed a robotic-assisted coronary artery bypass surgery remotely from New Delhi on a patient located 185 miles away in Jaipur, demonstrating the TSC's capability to extend surgical expertise globally [3][5] Group 3: Company Vision and Future Plans - SS Innovations aims to make robotic surgery affordable and accessible to a broader global population, with plans to expand its presence and technological offerings [8] - The company has refined the TSC since its initial showcase at the Society of Robotic Surgery Meeting in June 2024, indicating ongoing innovation and development [5]

Compact New Console Facilitates Performance of Telesurgeries from a Wide Range of Locations, including Physicians’ OfficesFORT LAUDERDALE, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful completion of the first telesurgery performed with the Company’s SSi Mant ...

Core Insights - SS Innovations International, Inc. reported a significant revenue increase of 192.5% year-over-year, reaching $12.8 million in Q3 2025, primarily driven by higher sales of the SSi Mantra 3 surgical robotic system [1][6][11] Financial Performance - Q3 2025 revenue rose to $12.8 million from $4.4 million in Q3 2024, with a gross profit increase of 166.0% to $6.2 million [6][11] - Gross margin for Q3 2025 was 48.1%, down from 52.8% in Q3 2024 [6] - The net loss for Q3 2025 was $3.7 million, consistent with the net loss of $3.2 million in Q3 2024 [6][11] - For the first nine months of 2025, total revenue increased by 123.0% to $28.0 million compared to $12.5 million in the same period of 2024 [6][8] - Cumulative surgeries performed using the SSi Mantra reached 6,057, including 56 telesurgeries and 319 cardiac procedures [6][12] Business Highlights - The number of SSi Mantra installations in Q3 2025 totaled 27, a 350.0% increase from 6 installations in Q3 2024 [6][11] - The cumulative installed base of SSi Mantra systems reached 127 across seven countries [6][11] - The company has received regulatory approval for the SSi Mantra in seven countries and is preparing to enter the U.S. and European Union markets [4][12] Upcoming Developments - The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025 and aims for CE marking certification in the EU in the first half of 2026 [4][12] - SS Innovations is scheduled to participate in investor conferences in November 2025, providing opportunities for management to engage with investors [9][10]

Core Insights - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [2][5] - The company will participate in upcoming investor conferences, including the UBS Global Healthcare Conference and the Stifel 2025 Healthcare Conference [3][4] Company Overview - SS Innovations is headquartered in India and aims to expand its global presence with cost-effective surgical robotic solutions [5] - The company's product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which support various surgical procedures, including robotic cardiac surgery [5] Product Performance - As of September 30, 2025, the SSi Mantra has a cumulative installed base of 125 systems across six countries, with 119 hospitals having installed the system [6] - Over 6,000 surgical procedures have been performed using the SSi Mantra, including 60 telesurgeries and 310 cardiac procedures [6] Product Features - The SSi Mantra is a modular, multi-arm surgical robotic system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and a virtual real-time image display [7] - It utilizes over 40 different types of robotic endo-surgical instruments and has been clinically validated in India for more than 100 different types of surgical procedures [8]

Core Insights - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to enhance the accessibility and affordability of robotic surgery globally [4][5]. Company Overview - SS Innovations is headquartered in India and aims to expand its global presence with its advanced and cost-effective surgical robotic solutions [4]. - The company’s product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which cater to various surgical procedures, including robotic cardiac surgery [4]. Recent Developments - As of September 30, 2025, the SSi Mantra has a cumulative installed base of 125 systems across six countries, with 119 hospitals utilizing the system [5]. - Over 6,000 surgical procedures have been performed using the SSi Mantra, which includes 60 telesurgeries and 310 cardiac procedures [5]. Upcoming Events - Dr. Sudhir Srivastava and Dr. Vishwa Srivastava will participate in the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025 [2][3]. - The Stifel conference will feature a group presentation at 4:40 p.m. Eastern Time, with a live webcast available on the company’s website [3]. Product Features - The SSi Mantra is a modular, multi-arm surgical robotic system equipped with advanced technology features, including 3 to 5 robotic arms, a 3D 4K monitor, and a virtual real-time imaging capability [6]. - It supports over 40 different types of robotic endo-surgical instruments, validated in more than 100 types of surgical procedures in India [6].

Core Insights - SS Innovations International, Inc. has successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital, marking a significant milestone in its regulatory process [1][2] - The company plans to submit a 510(k) premarket notification to the FDA in the fourth quarter of 2025, aiming for potential market clearance in the first half of 2026 [1][3] - The SSi Mantra has a cumulative installed base of 125 systems across six countries, with over 6,000 surgical procedures performed to date [4] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery more affordable and accessible globally [5] - The SSi Mantra system features a modular design with advanced technology, including multiple robotic arms and a 3D 4K monitor, supporting various surgical specialties [6] Regulatory Pathway - The company has shifted from a De Novo request to a 510(k) regulatory pathway, which is expected to provide speed and cost advantages in the approval process [4] - RQM+, a MedTech-focused CRO, has been engaged to assist with the 510(k) submission [2]

Core Viewpoint - SS Innovations International, Inc. has appointed Naveen Kumar Amar as Chief Financial Officer, effective September 24, 2025, succeeding Dr. Vishwa Srivastava, who will continue as CEO for Asia Pacific [1][2]. Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [6]. - The company’s product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which support various surgical procedures, including robotic cardiac surgery [6][9]. Leadership Experience - Naveen Kumar Amar brings over 25 years of global finance leadership experience across various industries and geographies, with expertise in financial accounting, planning, corporate finance, and governance [2][4]. - Amar has previously held significant positions, including Head of Finance & Commercial for SpiceXpress and Global CFO for Munch Ado India Private Ltd. [4]. Strategic Vision - The appointment of Amar is seen as a strategic move to enhance the financial operations of SS Innovations as the company aims to expand its global presence with the SSi Mantra surgical robotic system [3]. - Amar expressed his commitment to driving growth and delivering sustainable long-term shareholder value for SS Innovations [3].

Core Viewpoint - SS Innovations International, Inc. has appointed Naveen Kumar Amar as the new Chief Financial Officer, effective September 24, 2025, succeeding Dr. Vishwa Srivastava, who will continue as CEO for Asia Pacific [1][2][3]. Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [5]. - The company’s product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which support various surgical procedures, including robotic cardiac surgery [5]. Leadership Appointment - Naveen Kumar Amar brings over 25 years of global finance leadership experience across various industries and geographies, with expertise in financial accounting, reporting, planning, analysis, and corporate finance [2][3]. - Amar has previously held significant positions, including Global CFO for Munch Ado India Private Ltd. and Head of Finance & Commercial for SpiceXpress [2][3]. Strategic Vision - The company aims to expand the global presence of its advanced, cost-efficient surgical robotic systems, particularly the SSi Mantra [3]. - Amar expressed his commitment to democratizing access to advanced surgical robotic care and driving growth to deliver sustainable long-term shareholder value [3]. Product Details - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, and advanced imaging capabilities [6]. - It has been clinically validated in India for over 100 different types of surgical procedures, showcasing its versatility and effectiveness [6].

Core Insights - SS Innovations has successfully completed the world's first pediatric pyeloplasty telesurgery using its SSi Mantra surgical robotic system, demonstrating the system's capabilities in remote surgical procedures [2][3][5]. Company Overview - SS Innovations International, Inc. focuses on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [6]. - The company is headquartered in India and plans to expand its global presence with cost-effective surgical robotic solutions [6]. Product Details - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic command center, and advanced imaging capabilities, supporting various surgical specialties including pediatric surgery [7]. - The system has been clinically validated in over 100 different types of surgical procedures in India [7]. Market Opportunity - SS Innovations aims to address the unmet surgical robotic needs in the growing pediatric market, aligning with its mission to provide world-class care to underserved communities [5]. - The company has performed more than 50 telesurgeries at distances of up to 4,000 miles, showcasing the potential of the SSi Mantra in reaching remote patients [5]. Leadership Perspective - The Chairman and CEO of SS Innovations emphasized the advantages of robotic surgery, including precision, less invasiveness, and quicker recovery times, particularly important in pediatric care [3].

Core Insights - SS Innovations International, Inc. has successfully performed the world's first pediatric pyeloplasty telesurgery using its SSi Mantra surgical robotic system, demonstrating the system's capabilities in remote surgical procedures [1][3] - The SSi Mantra system is designed to make robotic surgery more precise, less invasive, and quicker, which is particularly beneficial in pediatric surgery [3] - The company aims to address the unmet needs in the growing pediatric surgical market by expanding the capabilities of the SSi Mantra system [4] Company Overview - SS Innovations develops innovative surgical robotic technologies with a mission to make robotic surgery affordable and accessible globally [5][6] - The SSi Mantra system features advanced technology, including modular robotic arms and a 3D 4K monitor, and has been clinically validated for over 100 different types of surgical procedures [7] Market Opportunity - The company is focusing on expanding its presence in the pediatric market, which is seen as a significant growth area for surgical robotics [4] - More than 50 telesurgeries have been performed using the SSi Mantra system, showcasing its versatility across various surgical categories [3]